Imatinib Mesylate Tablet, Film Coated
Product Images NDC 82249-021

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 82249-021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civica Script Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinibcontainerlabel100mg90stablets (Imatinibcontainerlabel100mg90stablets)

Imatinib Mesylate 100 mg film coated tablets packaging label showing 90 tablets per container. The label includes dosage strength, storage instructions, barcode, and details of distributor Civica Script LLC and manufacturer Hetero Labs Limited.*

FDA Label Image

Imatinibcontainerlabel400mg30stablets (Imatinibcontainerlabel400mg30stablets)

Imatinib Mesylate Tablets 400 mg film-coated tablet label by Civica Script LLC. Packaging indicates 30 tablets per container. Includes storage instructions, dosage reference, batch coding area, barcode, and manufacturer details from Hetero Labs Limited, India. Contains a QR code linking to product information.*

FDA Label Image

Imatinibfigure1 (Imatinibfigure1)

A Kaplan-Meier curve chart showing the percentage of patients without progression over time in months since randomization, comparing Imatinib Mesylate treatment arm (solid line) versus IFN+Ara-C treatment arm (dashed line). The chart includes patient progression counts, censorship data, hazard ratio with confidence intervals, and statistical significance.*

FDA Label Image

Imatinibfigure2 (Imatinibfigure2)

A Kaplan-Meier survival curve graph comparing the percentage of patients without progression to accelerated phase or blast crisis over 72 months since randomization. It includes two groups: Imatinib Mesylate arm (solid line) and IFN+Ara-C arm (dashed line). A data table shows patient numbers, hazard ratio, and statistical significance related to progression events for each treatment group.*

FDA Label Image

Imatinibfigure3 (Imatinibfigure3)

A survival curve chart comparing the probability of being alive and recurrence-free over time (in months) for patients treated with Imatinib 400 mg versus placebo. The x-axis represents survival time in months, ranging from 0 to 108, and the y-axis shows the probability from 0.0 to 1.0. The chart includes symbols for censored data and patient counts at various time points for both treatment groups.*

FDA Label Image

Imatinibfigure4 (Imatinibfigure4)

A Kaplan-Meier survival curve chart showing the probability of recurrence-free survival over time in months. The graph compares two groups treated with Imatinib for 12 months and 36 months, with survival probabilities on the y-axis and survival time in months on the x-axis. Censored observations are marked along the curves, and the chart includes corresponding hazard ratio and confidence interval data.*

FDA Label Image

Imatinibfigure5 (Imatinibfigure5)

A survival curve graph showing the probability of overall survival over time in months for two groups treated with Imatinib at 12 months and 36 months. The x-axis represents survival time in months, and the y-axis shows the probability of overall survival in percentage. The chart includes data points for events and censored observations, with supporting statistics such as hazard ratio and p-value.*

FDA Label Image

Imatinibstructure (Imatinibstructure)

Chemical structure of imatinib mesylate, the active ingredient shown with its molecular framework and the mesylate component (CH3SO3H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.